1. Home
  2. BOLT vs DKI Comparison

BOLT vs DKI Comparison

Compare BOLT & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.97

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$4.25

Market Cap

10.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
DKI
Founded
2015
2018
Country
United States
Hong Kong
Employees
N/A
19
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
10.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BOLT
DKI
Price
$3.97
$4.25
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
16.1K
6.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,695,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.75
$0.28
52 Week High
$7.20
$11.80

Technical Indicators

Market Signals
Indicator
BOLT
DKI
Relative Strength Index (RSI) 47.76 36.29
Support Level $3.90 $3.96
Resistance Level $4.46 $5.14
Average True Range (ATR) 0.24 0.19
MACD 0.01 -0.07
Stochastic Oscillator 39.10 2.35

Price Performance

Historical Comparison
BOLT
DKI

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

Share on Social Networks: